IMUC ImmunoCellular Therapeutics Ltd.

IMUC LOSS NOTICE: Rosen Law Firm Reminds ImmunoCellular Therapeutics, Ltd. of Important Deadline in Class Action – IMUC

Rosen Law Firm, a global investor rights law firm, reminds purchasers of ImmunoCellular Therapeutics, Ltd. securities (NYSEMKT:IMUC) from May 1, 2012 through December 11, 2013, inclusive (the “Class Period”) of the important June 30, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for ImmunoCellular investors under the federal securities laws.

To join the ImmunoCellular class action, go to http://rosenlegal.com/cases-1115.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

The complaint alleges that defendants during the Class Period made false and misleading statements and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote ImmunoCellular, which led the market to believe that ImmunoCellular’s clinical studies for its product candidate ICT-107 was going well. As a result of this scheme, ImmunoCellular’s share price was artificially inflated. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against ImmunoCellular, as well as other individuals and entities, for engaging in stock promotion schemes.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 30, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1115.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
10/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ImmunoCellular Therapeutics Ltd.

 PRESS RELEASE

ImmunoCellular Therapeutics: Notice of Proposed Settlement of Derivati...

ImmunoCellular Therapeutics: Notice of Proposed Settlement of Derivative Action LOS ANGELES, Aug. 09, 2019 (GLOBE NEWSWIRE) -- ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (OTC: IMUC), today issued the following announcement. The following is being released pursuant to an Order of the Superior Court of California, County of Los Angeles, entered on August 2, 2019, in the matter of: DAVID WIENER, derivatively and on behalf of IMMUNOCELLULAR THERAPEUTICS, LTD. v. FRACTOR et al., Case No. BC670134 NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION TO:               ALL OWNERS OF IM...

 PRESS RELEASE

The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf...

NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunoCellular Therapeutics, Ltd. (NYSEMKT: IMUC) who purchased shares between May 1, 2012 and December 11, 2013. The action, which was filed in the United States District Court for the Central District of California, alleges that the Company violated federal securities laws. In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misle...

 PRESS RELEASE

The Klein Law Firm Notifies Investors of a Class Action Filed on Behal...

NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunoCellular Therapeutics, Ltd. (NYSEMKT: IMUC) who purchased shares between May 1, 2012 and December 11, 2013. The action, which was filed in the United States District Court for the Central District of California, alleges that the Company violated federal securities laws. In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misle...

 PRESS RELEASE

IMMUNOCELLULAR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Su...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSEMKT:IMUC) of the June 30, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in ImmunoCellular stock or options between May 1, 2012 and December 11, 2013 and would like to discuss your legal rights, click here: www.faruqilaw.com/IMUC. There is no...

 PRESS RELEASE

IMUC SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Invest...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular Therapeutics") (NYSEMKT: IMUC) securities between May 1, 2012 and December 11, 2013. Click here to learn about the case: http://www.wongesq.com/pslra-sa/immunocellular-therapeutics-ltd?wire=2. There is no cost or obligation to you. Acco...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch